

# The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis.

Guideline ID: 2942

Published: 2023 Feb

**Joint Task Force on Practice Parameters | American Academy of Allergy, Asthma and Immunology | American College of Allergy, Asthma and Immunology**

*Rank MA, Chu DK, Bognanni A, et al. The Joint Task Force on Practice Parameters GRADE guidelines for the medical management of chronic rhinosinusitis with nasal polyposis. J Allergy Clin Immunol. 2023 Feb;151(2):386-398. [36 references] [PubMed](#)*

[View Original Guideline](#)

## Overview

### Guideline Objective

To evaluate the current evidence and provide guidance on the use of intranasal corticosteroids (INCS) and biologics for chronic rhinosinusitis with nasal polyposis (CRSwNP) and aspirin therapy after desensitization (ATAD) for aspirin (or nonsteroidal anti-inflammatory drug)-exacerbated respiratory disease (AERD)

**Note:** It is important to note that the current evidence on surgery for CRSwNP was not assessed for this guideline nor were management options other than INCS, biologics, and ATAD.

### Patient Population

People with CRSwNP, including those with AERD, aged 18 years and older

## Recommendations

### Recommendation Statements

Major interventions covered in this guideline include:

- Use of intranasal corticosteroids (INCS), biologics, and aspirin therapy after desensitization (ATAD) for AERD
- Treatment considerations during shared-decision making, including delivery method, severity of disease, and benefits and risks

**Note:** Full recommendation statements have not been provided because this guideline does not meet [EGT's systematic review of the evidence criteria](#). Refer to the [original guideline](#) for more information.

### Evidence Rating Scheme

Refer to the original guideline documentation for more information.

### Recommendation Rating Scheme

Refer to the original guideline documentation for more information.

## Related Content

### Supporting Documents

- [Supplement](#).
- [Benefits and Harms of Aspirin Desensitization for Aspirin-Exacerbated Respiratory Disease: A Systematic Review and Meta-Analysis](#); 2019 Dec.
  - [Supplementary Appendix](#).

- [Topical Corticosteroids for Chronic Rhinosinusitis with Nasal Polyposis: GRADE Systematic Review and Network Meta-Analysis; 2022 Dec.](#)
- [Comparative Efficacy and Safety of Monoclonal Antibodies and Aspirin Desensitization for Chronic Rhinosinusitis with Nasal Polyposis: A Systematic Review and Network Meta-Analysis; 2022 Apr.](#)
  - [Search Strategy: Biologics.](#)
  - [Supplementary Methods.](#)
- [Parameter and Guideline Development Process; 2019.](#)

## Implementation Tools

- [Slide Set.](#)

## Patient Education

No patient education materials available.

### Disclaimer

If you desire to use content from the original clinical practice guideline cited herein, you must contact the guideline developer directly to obtain permission rights.

ECRI's Guideline Profiles are designed to provide information and assist decision-making. Variations in practice will inevitably, and appropriately, occur when clinicians take into account the needs and preferences of individual patients, available resources, and limitations unique to an institution or type of practice. Every healthcare professional using these Guideline Profiles is responsible for evaluating the appropriateness of applying them in a clinical setting.